Efficacy and safety of nedaplatin versus cisplatin plus fluorouracil for treatment of esophageal neoplasms: A systematic review and meta-analysis_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

HUANG Daxin ^1,2 , HAN Songchen ² , JIN Dacheng ² , WANG Bing ^1,2 , ZHANG Siyuan ^1,2 , YANG Ning ^1,2 , HE Xiaoyang ^1,2 ,  DONG Xinchun ² ,  GOU Yunjiu ²

1. First Department of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, 730000, P. R. China;
2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China;

Corresponding author：

DONG Xinchun, Email: 3050319523@qq.com; GOU Yunjiu, Email: gouyunjiu@163.com

Keywords：

Nedaplatin; fluorouracil; cisplatin; esophageal neoplasms; systematic review/meta-analysis

DOI：

10.7507/1007-4848.202012037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically evaluate the efficacy and safety of nedaplatin versus cisplatin combined with fluorouracil in the treatment of esophageal neoplasms.Methods PubMed, EMbase, Web of Science, The Cochrane Library, CNKI, WanFang, VIP and CBM databases were searched by computer to investigate the randomized controlled studies about the clinical effects of nedaplatin combined with fluorouracil versus cisplatin combined with fluorouracil in the treatment of esophageal neoplasms. The retrieval time was from the establishment of the database to January 2021. And meta-analysis was performed using RevMan 5.4.Results A total of 12 randomized controlled studies involving 744 patients were included. The results of meta-analysis showed that the total effective rate of the nedaplatin group was better than that of the cisplatin group (P<0.05). The incidence of nausea, vomiting, diarrhea and renal impairment in the nedaplatin group was lower than that in the cisplatin group (P<0.05), but the incidence of leukopenia and hemoglobin decline was higher than that in the cisplatin group (P<0.05). There was no statistical difference in the incidence of liver injury, or platelet decline between the two groups (P>0.05).Conclusion Nedaplatin combined with fluorouracil has more advantages than cisplatin combined with fluorouracil in the treatment of esophageal cancer, the incidence of nausea, vomiting and diarrhea is lower, and the damage to kidney function is also smaller.

Citation： HUANG Daxin, HAN Songchen, JIN Dacheng, WANG Bing, ZHANG Siyuan, YANG Ning, HE Xiaoyang, DONG Xinchun, GOU Yunjiu. Efficacy and safety of nedaplatin versus cisplatin plus fluorouracil for treatment of esophageal neoplasms: A systematic review and meta-analysis. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(11): 1511-1516. doi: 10.7507/1007-4848.202012037 Copy

1.	Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol, 2015, 21(26): 7933-7943.
2.	Alsop BR, Sharma P. Esophageal cancer. Gastroenterol Clin North Am, 2016, 45(3): 399-412.
3.	白雪, 郑微, 李英滨, 等. 美洛昔康联合吉非替尼治疗食管癌的有效性及安全性分析. 现代肿瘤医学, 2020, 28(24): 4262-4265.
4.	苟云久, 马继龙, 韩松辰, 等. CircHIPK3 通过调控 p53-Akt-Mdm2 通路影响食管鳞癌的恶性表型. 肿瘤防治研究, 2019, 46(11): 987-993.
5.	Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Dis Esophagus, 2017, 30(2): 1-8.
6.	孙相辉. 奈达铂联合5-氟尿嘧啶治疗晚期食管癌患者的临床效果. 中国医药指南, 2020, 18(36): 107-108.
7.	Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol, 2013, 19(48): 9447-9452.
8.	Xu RH, Shi YX, Guan ZZ, et al. Phase Ⅱ clinical trial of home-produced nedaplatin in treating advanced esophageal carcinoma. Ai Zheng, 2006, 25(12): 1565-1568.
9.	房艳. 奈达铂联合 5-氟尿嘧啶治疗晚期食管癌的疗效分析. 中国医药指南, 2019, 17(36): 196-197.
10.	刘永玲. 奈达铂联合氟尿嘧啶治疗晚期食管癌的疗效观察. 中国基层医药, 2011, 18(12): 1641-1643.
11.	巴艳华. 奈达铂联合 5-氟尿嘧啶治疗晚期食管癌38例对免疫功能的影响. 现代诊断与治疗, 2019, 30(4): 567-569.
12.	李超. 奈达铂与 5-氟尿嘧啶联合用于治疗食管癌的疗效及安全性分析. 医学美学美容(中旬刊), 2013, (9): 77-78.
13.	汪俊. 奈达铂联合氟尿嘧啶治疗晚期食管癌的临床观察. 世界最新医学信息文摘, 2019, 19(25): 112.
14.	薛永飞. 氟尿嘧啶联合奈达铂治疗晚期食管癌的临床效果评价. 当代医学, 2013, (2): 32.
15.	施子夏, 张兵兵, 徐翔宇. 奈达铂联合氟尿嘧啶治疗晚期食管癌的疗效评价. 中国药业, 2017, 26(7): 52-54.
16.	赵春磊, 王娟. 氟尿嘧啶联合奈达铂化疗在晚期食管癌治疗中的临床研究. 系统医学, 2016, 1(3): 8-11.
17.	邹乐乐, 关红梅, 杨莹, 等. 奈达铂联合氟尿嘧啶与顺铂联合氟尿嘧啶治疗老年晚期食管癌效果的对比观察. 中国社区医师, 2015, 31(34): 21-22.
18.	林明哲, 李欣, 李晓琴, 等. 奈达铂联合氟尿嘧啶治疗晚期食管癌的疗效观察. 中国卫生产业, 2014, 11(26): 113-114.
19.	刘轲, 崔露琼, 蒋盼盼, 等. 感染与食管癌的研究进展. 食管疾病, 2020, 2(3): 161-164, 205.
20.	周毅. 奈达铂联合氟尿嘧啶方案在晚期食管癌的临床疗效分析. 吉林医学, 2012, 33(4): 764-765.
21.	Shimada M, Itamochi H, Kigawa J. Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag Res, 2013, 5: 67-76.
22.	王珊. 奈达铂联合 5-氟尿嘧啶治疗食管癌疗效与安全性分析. 基层医学论坛, 2016, 20(4): 490-491.
23.	张质钢, 王小虎, 杨克虎, 等. 奈达铂联合 5-氟尿嘧啶治疗晚期食管癌的 Meta 分析. 中国循证医学杂志, 2013, 13(1): 39-46.
24.	严丽华, 吴向坤. 奈达铂联合氟尿嘧啶在晚期食管癌治疗中的应用价值. 河南医学研究, 2015, 24(5): 55-56.
25.	冯淑娟. 奈达铂联合氟尿嘧啶治疗晚期食管癌的临床疗效分析. 中国继续医学教育, 2016, 8(3): 162-163.
26.	Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol, 2013, 19(34): 5598-5606.
27.	孙晓. 奈达铂联合氟尿嘧啶在晚期食管癌治疗中的临床应用价值分析. 中国实用医药, 2015, 10(5): 162-163.
28.	赵常有. 奈达铂、氟脲密啶联合放疗治疗中晚期食管癌疗效观察. 医药前沿, 2016, 6(35): 56-57.

1. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol, 2015, 21(26): 7933-7943.
2. Alsop BR, Sharma P. Esophageal cancer. Gastroenterol Clin North Am, 2016, 45(3): 399-412.
3. 白雪, 郑微, 李英滨, 等. 美洛昔康联合吉非替尼治疗食管癌的有效性及安全性分析. 现代肿瘤医学, 2020, 28(24): 4262-4265.
4. 苟云久, 马继龙, 韩松辰, 等. CircHIPK3 通过调控 p53-Akt-Mdm2 通路影响食管鳞癌的恶性表型. 肿瘤防治研究, 2019, 46(11): 987-993.
5. Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Dis Esophagus, 2017, 30(2): 1-8.
6. 孙相辉. 奈达铂联合5-氟尿嘧啶治疗晚期食管癌患者的临床效果. 中国医药指南, 2020, 18(36): 107-108.
7. Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol, 2013, 19(48): 9447-9452.
8. Xu RH, Shi YX, Guan ZZ, et al. Phase Ⅱ clinical trial of home-produced nedaplatin in treating advanced esophageal carcinoma. Ai Zheng, 2006, 25(12): 1565-1568.
9. 房艳. 奈达铂联合 5-氟尿嘧啶治疗晚期食管癌的疗效分析. 中国医药指南, 2019, 17(36): 196-197.
10. 刘永玲. 奈达铂联合氟尿嘧啶治疗晚期食管癌的疗效观察. 中国基层医药, 2011, 18(12): 1641-1643.
11. 巴艳华. 奈达铂联合 5-氟尿嘧啶治疗晚期食管癌38例对免疫功能的影响. 现代诊断与治疗, 2019, 30(4): 567-569.
12. 李超. 奈达铂与 5-氟尿嘧啶联合用于治疗食管癌的疗效及安全性分析. 医学美学美容(中旬刊), 2013, (9): 77-78.
13. 汪俊. 奈达铂联合氟尿嘧啶治疗晚期食管癌的临床观察. 世界最新医学信息文摘, 2019, 19(25): 112.
14. 薛永飞. 氟尿嘧啶联合奈达铂治疗晚期食管癌的临床效果评价. 当代医学, 2013, (2): 32.
15. 施子夏, 张兵兵, 徐翔宇. 奈达铂联合氟尿嘧啶治疗晚期食管癌的疗效评价. 中国药业, 2017, 26(7): 52-54.
16. 赵春磊, 王娟. 氟尿嘧啶联合奈达铂化疗在晚期食管癌治疗中的临床研究. 系统医学, 2016, 1(3): 8-11.
17. 邹乐乐, 关红梅, 杨莹, 等. 奈达铂联合氟尿嘧啶与顺铂联合氟尿嘧啶治疗老年晚期食管癌效果的对比观察. 中国社区医师, 2015, 31(34): 21-22.
18. 林明哲, 李欣, 李晓琴, 等. 奈达铂联合氟尿嘧啶治疗晚期食管癌的疗效观察. 中国卫生产业, 2014, 11(26): 113-114.
19. 刘轲, 崔露琼, 蒋盼盼, 等. 感染与食管癌的研究进展. 食管疾病, 2020, 2(3): 161-164, 205.
20. 周毅. 奈达铂联合氟尿嘧啶方案在晚期食管癌的临床疗效分析. 吉林医学, 2012, 33(4): 764-765.
21. Shimada M, Itamochi H, Kigawa J. Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag Res, 2013, 5: 67-76.
22. 王珊. 奈达铂联合 5-氟尿嘧啶治疗食管癌疗效与安全性分析. 基层医学论坛, 2016, 20(4): 490-491.
23. 张质钢, 王小虎, 杨克虎, 等. 奈达铂联合 5-氟尿嘧啶治疗晚期食管癌的 Meta 分析. 中国循证医学杂志, 2013, 13(1): 39-46.
24. 严丽华, 吴向坤. 奈达铂联合氟尿嘧啶在晚期食管癌治疗中的应用价值. 河南医学研究, 2015, 24(5): 55-56.
25. 冯淑娟. 奈达铂联合氟尿嘧啶治疗晚期食管癌的临床疗效分析. 中国继续医学教育, 2016, 8(3): 162-163.
26. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol, 2013, 19(34): 5598-5606.
27. 孙晓. 奈达铂联合氟尿嘧啶在晚期食管癌治疗中的临床应用价值分析. 中国实用医药, 2015, 10(5): 162-163.
28. 赵常有. 奈达铂、氟脲密啶联合放疗治疗中晚期食管癌疗效观察. 医药前沿, 2016, 6(35): 56-57.

Previous Article
The effect of blood type of colorectal patients on long-term survival: a real-world study based on DACCA database
Next Article
胰腺颈部Castleman病1例报道

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Efficacy and safety of nedaplatin versus cisplatin plus fluorouracil for treatment of esophageal neoplasms: A systematic review and meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content